Abstract: Compositions and methods for combinatorial drug discovery in nanoliter droplets are described. Novel synergistic agents that increase efficacy of antibiotic agents to treat bacterial infection are disclosed.
Type:
Grant
Filed:
October 9, 2018
Date of Patent:
January 31, 2023
Assignees:
THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Paul Blainey, Anthony Kulesa, Jared Kehe
Abstract: Disclosed are compositions comprising myokines and their methods of preparation and use. The disclosed myokine compositions and methods may comprise myokines having a molecular weight of greater than about 10 kDa such as myostatin and metrnl. The disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders. In particular, the disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders, such as cancer, and metabolic diseases and disorders, such as diabetes, non-alcoholic fatty liver disease, and heart disease.
Abstract: Pharmaceutical or food supplement preparation including alpha-lactalbumin and at least one short-chain fatty acid (SCFA) or a precursor or derivative thereof for use in the treatment of disorders of the central nervous system; the SCFA or its precursor or derivative may be contained in at least one first dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint and the alpha-lactalbumin in at least one second dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint, and said dosage units may be distinct units intended for simultaneous or separate administration or the preparation may consist of a pharmaceutical or food supplement composition comprising the at least one short-chain fatty acid or a precursor or derivative thereof and alpha-lactalbumin together with a carrier acceptable from the pharmaceutical or food standpoint.
Abstract: The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.
Type:
Grant
Filed:
February 13, 2019
Date of Patent:
January 10, 2023
Assignees:
Cedars-Sinai Medical Center, The Board of Trustees of the Leland Stanford Junior University
Inventors:
Ramachandran Murali, Aida Habtezion, Stephen J. Pandol
Abstract: The present invention pertains to: a botulinum toxin, epithelial cell growth factor, or hexapeptide fusion protein bound to skin tissues and cell-permeable peptides, or an epithelial cell growth factor mixed with skin tissues and cell-permeable peptides; and a composition comprising same. The fusion protein or the epithelial cell growth factor mixed with cell-permeable peptides has increased cell permeability compared to protein by itself, and is thus useful for improving the condition of skin, treating wrinkles, relieving muscle tension, and treating wounds.
Type:
Grant
Filed:
June 7, 2019
Date of Patent:
January 10, 2023
Assignee:
AVIXGEN INC.
Inventors:
Yi Yong Baek, Woo Ri Shin, Si Eun Park, Jun Sub Choi, Hye Cheong Koo
Abstract: There is provided in the present application a pharmaceutical composition comprising a peptide comprising the amino acid sequence of YEKLLDTEI (SEQ ID NO: 1) or a functional variant thereof, a pH adjusting agent, and a filler. The peptide is an active peptide for the treatment of a central nervous system injury. The present application also provides a pharmaceutical composition comprising a chimeric peptide comprising an active peptide and an internalization peptide, a pH adjusting agent, and a filler. The present application also provides medical use of a pharmaceutical composition comprising the active peptide or the chimeric peptide.
Abstract: Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
Type:
Grant
Filed:
August 24, 2021
Date of Patent:
January 3, 2023
Assignee:
CUREMARK, LLC
Inventors:
Joan M. Fallon, Matthew Heil, James J. Fallon, Janice Hughes
Abstract: The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). These stabilized CPP's are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried through a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell Penetrating Molecules (DCCPM's). The preferred BAC is an electrically low charge carrying oligonucleotide such as a phosphorodiamidate morpholino oligonucleotide (PMO).
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
January 3, 2023
Assignee:
SUTURA THERAPEUTICS LTD
Inventors:
Keith Foster, Wouter Eilers, Adam James Reginald Gadd
Abstract: This invention discloses certain methods of treating acute pancreatitis and inflammatory pancreatic disease or condition. The disclosed peptides and analogs can significantly lower the elevated blood amylase and lipase levels caused by acute pancreatitis and pancreatic inflammation, reduce the degree of injury observed in pancreatic histopathology caused by pancreatitis, and significantly lower the mortality rate of acute pancreatitis.
Abstract: The present invention relates generally to compositions and methods of using the same such as, for example, methods of treating the skin of a subject using a composition as described herein. The composition may comprise a diluent, a solvent, a penetration enhancing agent, a skin brightening agent, a skin renewing agent, a thickening agent, an anti-irritant, a chelating agent, an active pharmaceutical ingredient (API), optionally a pH adjustment agent, and optionally a preservative. The composition may further comprise L-arginine and/or L-citrulline and/or esters and/or derivatives thereof.
Abstract: Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.
Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Type:
Grant
Filed:
February 20, 2020
Date of Patent:
December 27, 2022
Assignees:
CORNELL UNIVERSITY, UNIVERSITY OF WASHINGTON
Inventors:
Hazel H. Szeto, Peter S. Rabinovitch, Dao-Fu Dai
Abstract: Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
December 13, 2022
Assignee:
The Regents of the University of California
Abstract: Methods of treating a fungal infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising one or more antifungal peptides selected from the group consisting of BmKn2, dBmKn2, Kn2-7, and dKn2-7 are described. Antifungal pharmaceutical compositions and dosage forms, including field-deployable dosage forms, comprising one or more of these antifungal peptides are also described.
Type:
Grant
Filed:
September 3, 2020
Date of Patent:
December 13, 2022
Assignee:
The United States of America as Represented by the Secretary of the Navy
Inventors:
Nancy Millenbaugh, Jeremy Wesley Gleaton, Dickson Kiprono Kirui, Sabrina Snyder, Crystal Rock
Abstract: Methods for treating neurological and other disorders, including autoimmune disorders are described. Also described is a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. Further a method is described that includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88.
Abstract: The present invention concerns Thymosin alpha 1 (T?1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
December 13, 2022
Assignee:
SciClone Pharmaceuticals International Ltd.
Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, which is connected at its CO—* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof.
Type:
Grant
Filed:
December 17, 2019
Date of Patent:
December 6, 2022
Assignee:
Novo Nordisk A/S
Inventors:
Jacob Kofoed, Patrick William Garibay, Jesper Lau
Abstract: The present invention provides a peptide exhibiting melanogenesis promoting activity. A peptide according to the present invention increases the activity and expression of tyrosinase and the expression of factors involved in melanogenesis, thereby exhibiting an outstanding effect on melanogenesis. The peptide of the present invention can be used for the prevention, alleviation, and treatment of hypomelanosis. The outstanding activity and stability stated above allow the peptide of the present invention to be very favorably applied to medicines, quasi-medicines, and cosmetics.